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Abstract
Background: A serological marker for pancreatic cancer may allow for early detection and potentially more effective
treatments. Pro-carboxypeptidase A (pro-CPA) is produced exclusively in the pancreas and converted to its active form,
CPA, in the intestinal lumen. We hypothesized that alterations in serum pro-CPA and/or CPA may be useful as a diagnostic
test for pancreatic cancer. Patients and methods: Serum samples obtained from 34 patients with pancreatic adenocarcinoma
prior to surgical intervention and 64 control patients were assayed for pro-CPA and CPA. A variety of statistical methods
was used to evaluate the utility of these measurements individually and in combination to classify the samples with respect to
the presence or absence of pancreatic adenocarcinoma. Results: Because of positive skewing of the data in some populations,
transformation of the data to natural logarithmic scales was used and resulted in normal distributions. All pancreatic cancer
patients had ln(CPA) levels within or below the normal range defined as two standard deviations from the control group
mean (/2.7149/0.413). Ln(pro-CPA) levels in 24 of 34 cancer patients were outside the normal range of the control group
(0.3069/0.33). Pancreatic cancer patients with ln pro-CPA values within the control range had low ln CPA, advanced stage
and/or evidence of pancreatic insufficiency. While each of these individual values (ln pro-CPA or ln CPA) does not
adequately separate all control from cancer patients, a bivariate classification rule is presented that uses both ln pro-CPA
and ln CPA simultaneously to predict the presence of pancreatic cancer with a sensitivity of 91% and a specificity of 95%.
Conclusions: The data presented suggest that abnormalities in serum pro-CPA and CPA levels are associated with the
presence of pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of death
due to malignancy among men and the fifth among
women in the USA [1]. Some 30 300 cases will be
diagnosed this year and 29 700 Americans are ex-
pected to die of the disease this year. With a 5-year
survival rate of B/4% it is the deadliest of the 60
malignancies surveyed for the Annual Cancer Statis-
tics Review [2]. Currently no radiologic or che-
motherapeutic modalities are known that have
substantially altered this dismal outlook. Recent
reports suggest that improved outcomes can be
obtained following surgical resection in selected
patients [3,4]. Only 20% of the patients who present
with pancreatic adenocarcinoma are candidates for
resection and in these there is a strong inverse
correlation between surgical success and the stage at
presentation [3,4]. Earlier detection of the malignancy
will allow for more effective treatments and result in
increased survival.
Considerable effort has been expended in a search
for serological markers that might serve to provide a
warning of the initiation of malignant growth within
the pancreas, including glycoproteins, mucins, and
enzymes [5]. Although some of the markers, most
notably CA 19-9, were shown to have utility as
diagnostic adjuncts to imaging techniques none have
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been shown capable of meeting the requirements for a
successful screening tool. In general the failure has
been a lack of adequate specificity either at the level of
multiple tissue origins or an obfuscating elevation in
the marker concentrations in benign pathological
states. The most marked elevations in CA 19-9 are
seen in patients with advanced unresectable and
metastatic disease, making CA 19-9 unreliable as an
early diagnostic test [6].
Carboxypeptidase A (CPA) originates exclusively in
the pancreas [7] and it therefore immediately met the
criterion of tissue specificity as an alternative to
previous markers. With the recent development of
specific and sensitive assays for CPA and its precursor
pro-carboxypeptidase A (pro-CPA) it became possible
to establish baseline values for these two proteins in
the healthy adult [8,9] and to contrast these concen-
trations with those to be found in patients with diverse
pancreatic pathologies. We previously established that
pancreatitis was characterized by elevations in both
CPA and pro-CPA and could be distinguished from
pancreatic cancer where our initial observation was
that only pro-CPA was elevated [10]. It was also noted
that in those patients whose malignancy had advanced
to the state of pancreatic insufficiency the serum pro-
CPA concentrations could fall to below normal
values. The results presented here suggest the associa-
tion of abnormal serum pro-CPA and CPA with
pancreatic cancer.
Patients and methods
Study population
Serum samples were obtained from 34 patients
diagnosed with carcinoma of the head of the pancreas
before surgical exploration or resection (Table I). The
presumptive preoperative diagnosis of pancreatic
carcinoma was made by clinical presentation and
imaging studies. Adenocarcinoma of the pancreas
was confirmed by pathologic evaluation of the re-
sected or biopsy specimens. Clinical data from the
pancreatic cancer patients was obtained including
stage, and evidence of pancreatic insufficiency (diar-
rhea at presentation and/or new-onset or worsening
diabetes mellitus). Serum samples obtained from 64
healthy asymptomatic adult blood donors were used
as a control group. All serum samples were stored at
/208C before assay.
CPA and pro-CPA assay
Serum pro-CPA and CPA were measured by investi-
gators blinded to patient diagnosis by the methodol-
ogy described previously [8,9]. Briefly, Ellman’s
reagent [5,5?-dithio-bis(2-nitrobenzoic acid)], DL-
benzylsuccinic acid, clostripain, and dithiothreitol
(Cleland’s reagent) were purchased from Sigma
(St Louis, MO, USA). Semimicro cuvettes were
purchased from Fisher. The substrate N-acetyl-
phenylalanyl-3-thiaphenylalanine (NAcPSP) was ob-
tained from Peptides International (Louisville, KY,
USA). CPA activity was determined by adding serum
samples to Ellman’s reagent and incubated for 5 min
at 228C, to allow free sulfhydryl groups in the serum
to react to completion. NAcPSP was then added and
the mixture was immediately dispensed in equal
volumes into each of three plastic cuvettes with 1 cm
path lengths. One of these cuvettes (the ‘blank’)
contained 1 ml of a CPA inhibitor, 0.4 M DL-benzyl
succinic acid, and the other two cuvettes (the ‘tests’)
each contained 1 ml of water. An initial absorbance
was recorded and then the cuvettes were incubated at
378C. Absorbance was monitored at 412 nm every
hour or hour and a half for a total of 3 h with a Zeiss
PM6 spectrophotometer. After 3 h, the absorbance
was measured using one common cuvette to insure
the precision of the cuvettes. Activation of the pro-
CPA in the serum samples was achieved with clos-
tripain. Serum (0.040 ml) was combined with
0.020 ml of clostripain (500 units/ml) and incubated
at 378C for 5 min, after which time 1.440 ml Ellman’s
reagent and 1.020 ml H2O were added. After incuba-
tion for 5 min at room temperature, the assay
proceeded as previously outlined for CPA with the
addition of NAcPSP.
Statistical methods
The distributions of CPA and pro-CPA were exam-
ined for the control group and for pancreatic cancer
patients using graphical displays. The examination of
the differences between the apparently healthy con-
trols and cancer patients with respect to CPA and
pro-CPA levels was carried out using t tests after
appropriate transformations to natural logarithm
scales to account for the long-tailed distributions.
KolmogorovSmirnoff tests were used to assess the
normality of these distributions. Since the stage of
pancreatic cancer was also thought to be related to
levels of CPA and pro-CPA, patient samples were also
grouped by pathologic stage. The levels of these
variables were then compared among pathologic stage
groups: group 1 (stage III disease (T1T3, N0,
M0)), group 2 (stage III disease (T1T3, N1, M0) or
stage IV disease (T4 or any T, any N, M-1)). A one-
way analysis of variance was then used to determine if
levels of pro-CPA (and CPA) vary with pathologic
stage of disease. Pairwise comparisons were carried
out using Fisher’s protected LSD to adjust for multi-
ple comparisons.
To evaluate the potential utility of pro-CPA (or
CPA) as a screen for the presence of pancreatic
cancer, linear discriminant functions of each variable
(ln CPA or ln pro-CPA) individually and jointly were
developed to discriminate between the cancer and
apparently normal samples. The misclassification
probabilities (false negative and false positive rates)
452 P. Shamamian et al.
estimated from these approaches did not provide
adequate sensitivity and specificity to be useful.
The method of choice that provided sensitivity and
specificity that would be associated with a potentially
useful screening test was a classification rule based on
the confidence ellipsoids of the bivariate normal
distribution of (ln pro-CPA, ln CPA) in the normal
controls. A suggestion for a screening test based on
this rule that incorporates the positive correlation
between the two markers and its sensitivity and
specificity is provided.
Results
Pro-CPA and CPA activity in asymptomatic blood donors
The availability of a direct serum assay for CPA and
the finding that clostripain could carry out the
quantitative activation of its precursor, pro-CPA, to
the free enzyme made it possible to establish the
concentrations of these two molecules in the sera of
healthy adults. While the baselines for these molecules
have been published [8,9] the side-by-side compar-
ison of these two values for individual sera have not.
Table II (a) and (b) provide summary statistics for
CPA and pro-CPA for apparently healthy group of
subjects. The distributions of CPA and pro-CPA
are positively skewed, that is, long tailed to the right.
The distributions of the transformed values, i.e.
ln(CPA) and ln(pro-CPA), are normally distributed
(KolmogorovSmirnov (KS) normality test, p/0.34
and 0.56, respectively) (Figure 1).
Table II (c), and (d) provide the summary statistics
for the distributions of the ln-transformed values of
pro-CPA and CPA for apparently healthy controls.
The mean ln (pro-CPA) is 0.306 with standard
deviation 0.33 (see Table IId). For such normally
distributed variables, approximately 95% of the ob-
servations will be within two standard deviations
(SDs) of the mean (/0.35, 0.97). For ln(CPA) the
mean (SD) is /2.71 (SD/0.413) with 95% of the
observations within the two SD range of (/3.54,
/1.89) (see Table IIc).
CPA and pro-CPA activity in pancreatic cancer patients
The role of CPA activity in pancreatic cancer, nar-
rowed to ductal adenocarcinoma of the head of the
Table I. Serum pro-CPA and CPA activity in 34 patients with adenocarcinoma arising in the head of the pancreas grouped by AJCC stage:
outlined patients presented with pancreatic insufficiency.
Patient Age Sex Diabetes Diarrhea Stage proCPA(U/L) LN(Pro-CPA) CPA(U/L) LN(CPA) Resected
1 76 M N N 1 12.1 2.5 0.078 /2.6 Y
2 74 M Y N 1 5.6 1.7 0.023 /3.8 Y
3 61 M N N 1 3.5 1.2 0.123 /2.1 Y
4 71 M N N 1 2.6 0.9 0.053 /2.9 Y
5 65 M N Y 2 7.2 2.0 0.084 /2.5 Y
6 66 M N N 2 6.4 1.9 0.103 /2.3 Y
7 82 M N N 2 5.5 1.7 0.049 /3.0 Y
8 58 M N N 3 43.9 3.8 0.061 /2.8 Y
9 69 M N N 3 36.4 3.6 0.151 /1.9 Y
10 50 F N N 3 16.6 2.8 0.065 /2.7 Y
11 60 M N N 3 15.0 2.7 0.121 /2.1 Y
12 52 M N N 3 7.0 1.9 0.008 /4.8 Y
13 80 M N Y 3 4.2 1.4 0.033 /3.4 Y
14 57 M N N 3 3.6 1.3 0.139 /2.0 Y
15 90 M N N 3 3.3 1.2 0.038 /3.3 Y
16 65 F N Y 3 2.6 0.9 0.061 /2.8 Y
17 73 F N N 3 2.1 0.7 0.023 /3.8 Y
18 61 M Y Y 3 2.0 0.7 0.008 /4.8 Y
19 62 F N N 3 1.4 0.4 0.033 /3.4 Y
20 83 M N N 3 1.4 0.3 0.016 /4.1 Y
21 63 M N N 3 1.1 0.1 0.041 /3.2 Y
22 72 F Y Y 3 0.6 /0.5 0.074 /2.6 Y
23 59 F Y Y 3 0.5 /0.8 0.004 /5.5 Y
24 37 M Y Y 3 0.2 /1.8 0.033 /3.4 Y
25 68 M N N 4 36.8 3.6 0.082 /2.5 N
26 72 M N Y 4 23.6 3.2 0.033 /3.4 N
27 65 M N N 4 14.6 2.7 0.106 /2.2 N
28 53 M N N 4 7.2 2.0 0.01 /4.6 Y
29 70 M N N 4 5.2 1.7 0.041 /3.2 N
30 74 F Y N 4 2.4 0.9 0.012 /4.4 N
31 60 F Y Y 4 1.1 0.1 0.020 /3.9 N
32 68 F N N 4 0.8 /0.2 0.034 /3.4 N
33 73 F N Y 4 0.7 /0.4 0.119 /2.1 N
34 62 M Y Y 4 0.5 /0.7 0.074 /2.6 N
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pancreas, was evaluated similarly to that of controls.
The distribution of CPA is non-normal (KS, p/
0.037) while the distribution of ln(CPA) is normal.
A summary of the descriptive statistics of ln(CPA) for
34 pancreatic cancer patients is presented in Table IIc.
All the pancreatic cancer patients had a value of
ln(CPA) within or below the normal range (mean9/
2 SD) for the healthy population. Serum levels of this
peptidase had been found, by several laboratories, to
be consistently elevated in pancreatitis [1114]. It is
perhaps not surprising that a malignant process that is
known to proceed so insidiously, in the absence of
systemic inflammation, does not result in premature
activation of pro-CPA. Similar distributions are shown
for ln (pro-CPA) in Table IId. Note that 19 of 34
cancer patients had levels of ln(pro-CPA) that are
above the ‘normal range’ of ln(pro-CPA) levels of
the controls, and 5 had ln(pro-CPA) levels below the
normal range of the controls (Table I). Of the cancer
patients with ln(pro-CPA) within the range of normal,
four had lnCPA values below the 95th percentile
distribution of controls. Of the 34 cancer patients
only 4 patients had ln(CPA) and ln(pro-CPA) values
within the range of the controls, all were advanced
stage and one of these patients (patient 34, Table I)
had evidence of pancreatic insufficiency.
Cancer patients vs controls
The mean ln(CPA), /3.18, for pancreatic cancer
patients is significantly lower than that for healthy
donors (/2.74) (p/0.002), and the mean of ln(pro-
CPA) (1.28) for cancer patients is significantly greater
than the mean (0.305) for the controls (p/0.0002).
This suggests that a low ln(CPA) and an increased
ln(pro-CPA) might be useful to differentiate cancer
patients from healthy subjects.
Since the stage of pancreatic cancer has an effect on
the outcome, patients with pancreatic cancer were
further divided into subgroups according to patholo-
gic staging. Group 1 included stage III disease (T1
T3, N0, M0), group 2 contained stage III disease
(T1T3, N1, M0) and stage IV disease (T4 or any T,
any N, M-1). Table IIIa shows the results of the one-
way analysis of variance, suggesting that there are
significant differences among the three groups of
subjects with respect to ln(CPA). From the pairwise
tests (adjusted for multiplicity), we note that there are
significant differences between healthy patients and
stage IIIIV patients (pB/0.001) and between stage
III and stage IIIIV patients (p/0.034). Table IIIb
provides the results of a similar analysis of ln(pro-
CPA) comparing stage III, stage IIIIV, and con-
trols. Again, there are significant differences between
controls and stage III (and stage IIIIV) patients,
although there is no significant difference between the
two groups of pancreatic cancer patients.
To evaluate the utility of the levels of ln(CPA) and
ln (pro-CPA), as potential screens for the presence of
pancreatic cancer, misclassification rates were esti-
mated for various cut-off values of these markers.
Note that there is a large observed overlap in the
distributions of ln(CPA) and ln(pro-CPA) for both
the healthy and cancer groups in Figure 1. From
Table IV, we note that for any cut-off point with a false
positive rate (1-sensitivity) less than 10%, the false
negative rates are greater than 60% and 30% in
Table II. Distribution of CPA and pro-CPA for healthy subjects and
patients with pancreatic cancer.
Status n Mean SD SE KS test*
(a) CPA (U/L)
Healthy 64 0.071 0.031 0.004 0.151
Cancer 34 0.057 0.041 0.007 0.037
(b) pro-CPA (U/L)
Healthy 64 1.428 0.45 0.056 0.202
Cancer 34 8.162 11.187 1.919 B/0.0001
(c) ln(CPA)
Healthy 63 /2.714 0.413 0.052 0.343
Cancer 34 /3.183 0.917 0.157 0.105
(d) ln(pro-CPA)
Healthy 63 0.306 0.33 0.042 0.562
Cancer 34 1.281 1.367 0.234 0.5
*KolmogorovSmirnov test for normality p value.
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Figure 1. Distributions of (A) ln(CPA) and (B) ln(proCPA) for cancer (') and control groups (m).
454 P. Shamamian et al.
ln(CPA) and ln (pro-CPA), respectively. These results
are not surprising given the large overlap of the
observed distributions of the measures in the control
and cancer groups.
Since the two variables are positively correlated in
the normal controls (0.43) and in the cancer patients
(0.33), we first developed a linear discriminant func-
tion based on both of these variables. Although the
means of both ln CPA and ln pro-CPA among the
controls (0.31, /2.71, respectively) differ signifi-
cantly from the means among the pancreatic cancer
patients (1.28, /3.18, respectively, pB/0.00001,
Hotelling’s T), the misclassification rates remain
substantial. For any cut-off point based on the linear
discriminant function, if the false positive rate (1-
sensitivity) was less than 10%, the false negative rate
was 24% or greater.
We then sought to improve these misclassification
rates by developing a classification rule based on the
bivariate normal distribution of the transformed
values of the markers. We developed confidence
ellipsoids for the control group. Subjects within
the ellipse would be classified as normal and those
outside the ellipse as ‘cancer’. The size of this
confidence ellipsoid based on this bivariate normal
distribution was varied to include up to 95% of the
controls. From Figure 2, we note that the rule does
provide separation between these two groups. The
ellipse, denoted as:
f((y1, y2),u), where:
f ((y1; y2); u)12:1(y10:31)
2
9:2(y10:31)(y22:71)
7:7(y22:71)
2u
(y1, y2)/(ln(pro-CPA), ln(CPA)), and u is a cut-
off point (or threshold). An individual with given
values of (ln(pro-CPA), ln(CPA)) will be classified
as one with pancreatic cancer if and only if
f((ln(proCPA), ln(CPA)),u)/0, where u determines
the size of the confidence ellipsoid. Table IV shows
the false negative and positive rates for this classifica-
tion rule f(y, u) for selected confidence levels and u . If
we choose the 93% confidence ellipse with corre-
sponding u/5.3, both the observed false negative rate
(0.09) and the false positive rate (0.05) in our data are
Table III. Comparison of controls with pancreatic cancer patients.
Difference of mean 95% CI
Groups Estimate Lower Upper p value
(a) ln(CPA)
Healthy vs cancer stage II 0.017 /0.476 0.511 0.944
Healthy vs cancer stage IIIIV 0.585 0.301 0.87 B/0.001
Stage II vs stage IIIIV 0.568 0.043 1.093 0.034
(b) ln(pro-CPA)
Healthy vs cancer stage II /1.399 /2.066 /0.732 B/0.001
Healthy vs cancer stage IIIIV /0.865 /1.251 /0.48 B/0.001
Stage II vs stage IIIIV 0.533 /0.177 1.244 0.139
The pairwise comparisons were conducted via Fisher’s protected LSD methods.
Table IV. Misclassification rates for cut-off values of (ln(CPA),
ln(pro-CPA)).
Cut-off point u False negative False positive
1.83 0.03 0.48
2.41 0.03 0.32
3.22 0.03 0.19
4.61 0.09 0.1
5.3 0.09 0.05
5.5 0.12 0.05
5.99 0.12 0.05
7.38 0.15 0.02
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Figure 2. Ellipse denoted as f (y, u ), where y/(ln(pro-CPA),
ln(CPA)) and u is a cutpoint (or threshold), that results from the
best choice of a nonlinear discriminant function of (ln(pro-CPA),
ln(CPA)) to distinguish controls from the pancreatic cancer
patients. The formula is given explicitly in the text. An individual
with given values of (ln(pro-CPA), ln(CPA)) will be classified as
one with pancreatic cancer if the plot of these values lies outside
the ellipse. This nonlinear discriminant function suggests that
ln(pro-CPA)/ln(CPA) (and hence pro-CPA/CPA) may be a useful
serologic marker for detection of pancreatic cancer with a sensitivity
of 91% and specificity of 95%. Note that the majority of pancreatic
cancer patients are outside the ellipse, the four within the ellipse
have advanced (stage III or IV) lesions. Four control patients were
represented outside the ellipse, which clinically would have led to
more specific radiographic evaluations in these patients.
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quite small. If we choose the 95% confidence ellipse
with u/5.99, the observed false negative rate is 0.12
and the observed false positive rate is 0.05. These
results suggest that (ln(pro-CPA), ln(CPA)) (and
hence (pro-CPA, CPA)) may be a useful serological
marker for the detection of pancreatic cancer. A
screening test based on this procedure correctly
identifies 95% of the controls with an estimated
sensitivity of 8891%.
Of the 34 cancer patients, only 3 patients had values
within the normal range defined by the ellipse (shown
in Figure 2). All three were advanced stage without
evidence of pancreatic insufficiency (Table I, patients
19, 21, and 32).
Discussion
The opportunity to intervene at an early stage of
pancreatic cancer can improve the prognosis of
patients with this aggressive disease. Pro-CPA and
CPA are produced exclusively by the pancreas and
therefore the respective serum concentrations are
affected by pathologic processes in the gland. Evalua-
tion of CPA and pro-CPA as markers of pancreatic
cancer was initially hampered by the observation that
the distributions in the populations studied were not
uniformly normal. After transformations to natural
logarithmic scales, the distributions were normal, and
evaluation of CPA and pro-CPA in pancreatic disease
was therefore possible. For the purposes of the
following discussion, references to CPA and pro-
CPA in pancreatic cancer are based on logarithmic
scales. These data demonstrate that abnormalities in
serum concentrations of CPA and pro-CPA are
associated with pancreatic cancer and may be used
to discriminate between healthy patients, early and
late stages of pancreatic cancer. Using a bivariate
classification rule such f((ln(pro-CPA), ln(CPA)),5.3)
alone may provide an effective screening test for
pancreatic cancer including early stage pancreatic
cancer and elevations of pro-CPA may be of help for
the early diagnosis. Finally, we hypothesize that
changes in serum CPA and pro-CPA result from the
effect of the tumor on the normal gland.
At first glance it might seem paradoxical that
adenocarcinoma of the head of the pancreas which
originates in the ductal cells of the gland should result
in an elevation in serum concentrations of pro-CPA, a
protein that is made exclusively in the acinar cells. We
hypothesize that the developing pancreatic mass
obstructs the pancreatic duct, resulting in injury to
the upstream acinar cells and release of pro-CPA. It
would be expected that in a healthy individual in
whom a pancreatic ductal tumor had initiated, with
time, there would be increasing serum levels of pro-
CPA, as more and more acinar cells were affected by
the obstructed pancreatic duct. However, at some
point the continuing destruction of normally func-
tioning acinar cells would no longer support further
increases and the pro-CPA would decline, indeed
towards the end of the process, to values below its
original normal value. This latter period would
correspond to the clinically observed pancreatic
insufficiency that is often noted, with the accompany-
ing diarrhea and diabetes, frequently associated with
advanced pancreatic cancer. With respect to CPA, in
the absence of inflammation as in pancreatitis, there
would be no mechanism for activation of the pro-
CPA. Hence these values would remain within the
usual range until loss of functioning acinar cells would
cause an increasing decline in the serum content of
the active enzyme.
The data presented in Table I are striking in that all
seven patients with early pancreatic cancer (stage I
and II) have pro-CPA above the range control and fall
outside the ellipse described by the nonlinear dis-
criminant function. Furthermore, the CPA levels in
this group of patients were within the range of
controls, suggesting that decreasing CPA is a late
event associated with advanced pancreatic cancer.
Although we hypothesized that elevated pro-CPA is
a marker for pancreatic cancer, only 19 of the 34
individuals displayed pro-CPA values above the nor-
mal threshold. In fact, all patients who did not have
pro-CPA elevations above threshold presented with
stage III and IV disease. This is in agreement with the
general recognition that symptoms of pancreatic
cancer present late in the disease process. Therefore,
it would be anticipated that a substantial fraction of
the remaining group would be in the phase of the
malignancy where a major portion of the gland would
be nonfunctional. In direct biochemical support of
this supposition it can be seen that four patients (nos
22, 23, 24, and 34) show less pro-CPA than the lower
threshold for normal (/0.35) and that four of the
remaining nine (nos 17, 18, 20, and 31) are char-
acterized by lower levels of the active enzyme, CPA,
than the lower limit for that parameter (/3.54).
Moreover, it is in this group that a disproportionate
amount of the diarrhea and diabetes occur in these
patients.
Finally, it is apparent that neither CPA nor pro-
CPA alone will provide the best measure of pancre-
atic cancer development. The classification rule in
Figure 2 suggests that it may be possible to estimate
risk for presence of pancreatic cancer based on these
two measures jointly. This function relates the regula-
tion of CPA activity as it is affected by production,
activation, and excretion, which should remain at a
steady state. Perturbations of this steady state from a
growing cancer will be apparent as an individual falls
outside the ellipse in Figure 2. The majority of
pancreatic cancer patients in this study are outside
the ellipse. The three pancreatic cancer patients
within the ellipse have advanced (stage III or IV)
lesions, which is consistent with our hypothesis of
pseudo-normalization of pro-CPA/CPA values in late
stage disease. Four control patients were represented
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outside the ellipse, which clinically would have led to
more specific radiographic evaluations in these pa-
tients to definitively demonstrate absence of a pan-
creatic lesion. Although there is a high sensitivity and
specificity, because of the low frequency of pancreatic
cancer in the general population, screening for pan-
creatic cancer with CPA and pro-CPA will invariably
lead to numerous false positive diagnoses. Therefore
we propose to use this serum assay as an indication to
refer patients for a sensitive imaging diagnostic study
(i.e. CT, MRCP or EUS) [1517]. In particular,
elevations in pro-CPA in an asymptomatic individual
would warrant a more definitive study of the pancreas
to rule out a malignancy.
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